BioCentury
ARTICLE | Clinical News

ApoGraft: Ph I/II ApoGraft01 ongoing

April 20, 2017 9:50 PM UTC

An independent DSMB approved the enrollment of the next 2 patients in the first cohort of the open-label, Israeli Phase I/II ApoGraft01 trial evaluating transplanted ApoGraft exposed to FASL. The DSMB...

BCIQ Company Profiles

Cellect Biotechnology Ltd.